BridgeMD
New treatment option for Non-small Cell Lung Cancer
Official title Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
ClinicalTrials.gov ID: NCT05122806
What this study is testing
What is RNAseq?
RNAseq is an investigational medicine, being studied as a potential treatment for non-small cell lung cancer.
Also referred to as DNA NGS.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- BioEXALK is a prospective study evaluating the biological characteristics of advanced ALK-rearranged NSCLC treated with next generation TKIs in first line, included in the national EXPLORE ALK cohort (GFPC 03-2019), a non-interventional, national, multi-center cohort of ALK-rearranged NSCLC patients. BioExALK study will be proposed to every patient included in the Explore ALK GFPC 03-2019 study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Stage IIIB/IV NSCLC non eligible to locoregional treatment with curative intent
- ALK rearrangement confirmed by IHC and/or FISH or NGS according to local methods
- Patient included in the EXPLORE ALK study
- Age \> or = 18 years
- Patient treated with first-line new generation ALKi
You likely can't join if
- Patients who do not wish to participate in Bioexalk
- Patients under guardianship
See the full eligibility criteria
- Stage IIIB/IV NSCLC non eligible to locoregional treatment with curative intent
- ALK rearrangement confirmed by IHC and/or FISH or NGS according to local methods
- Patient included in the EXPLORE ALK study
- Age \> or = 18 years
- Patient treated with first-line new generation ALKi
- Patient agrees to sign an informed consent form and to collect blood samples at inclusion, first tumor evaluation and progression and for whom tumor biopsy at diagnosis is available
- Patient enrolled in the french National Health Insurance program or with a third- party payer
- Patients who do not wish to participate in Bioexalk
- Patients under guardianship
The study team makes the final eligibility decision.
Where it's taking place
- Saint-Denis, La Réunion, France
- Aix-en-Provence, France
- Amiens, France
- Angers, France
- Annecy, France
- Brest, France
- Caen, France
- Chambéry, France
- Clermont-Ferrand, France
- Créteil, France
- Évreux, France
- La Roche-sur-Yon, France
- Le Chesnay, France
- Le Mans, France
- Lille, France
- Limoges, France
- Lorient, France
- Lyon, France
- Mantes-la-Jolie, France
- Marseille, France
+ 21 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Saint-Denis, La Réunion, France; Aix-en-Provence, France; Amiens, France; Angers, France; Annecy, France; Brest, France and 35 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.